Biocryst Pharmaceuticals (BCRX) Gross Profit (2010 - 2026)

Biocryst Pharmaceuticals (BCRX) has reported Gross Profit for 16 consecutive years, with $214.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Gross Profit rose 33.54% year-over-year to $214.4 million; the trailing twelve-month figure through Jun 2026 stood at $513.8 million (down 4.99% YoY), and the FY2025 full-year result was $855.8 million, up 95.18% from the prior year.
• Gross Profit climbed to $214.4 million in Q2 2026 per BCRX's latest filing, from $151.0 million in the prior quarter.
• Across five years, Gross Profit topped out at $214.4 million in Q2 2026 and bottomed at -$8.8 million in Q4 2025.
• Historically, Gross Profit has averaged $102.5 million across 5 years, with a median of $91.7 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Gross Profit jumped 278.25% in 2022, then slumped 107.03% in 2025.
• Over 5 years, Gross Profit stood at $77.2 million in 2022, then gained by 19.03% to $91.8 million in 2023, then soared by 36.58% to $125.4 million in 2024, then slumped by 107.03% to -$8.8 million in 2025, then jumped by 2532.61% to $214.4 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $214.4 million, $151.0 million, and -$8.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.